AstraZeneca and Foundation Medicine to collaborate on diagnostic assays

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

AstraZeneca and Foundation Medicine Inc. will collaborate to develop companion diagnostic assays to identify patients most likely to benefit from medicines within AstraZeneca’s oncology pipeline. AstraZeneca will utilize the Quality Systems Regulations-compliant version of Foundation Medicine’s comprehensive genomic profiling assay for solid tumors to enroll patients into clinical trials of therapies that target genomically driven...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

The U.S. Preventive Services Task Force is at risk of losing the expertise, evidence-review infrastructure, and institutional culture that has made it a model for evidence-based medicine. In July 2025, David Ransohoff, a gastroenterologist and clinical epidemiologist in the Division of Gastroenterology and Hepatology at University of North Carolina School of Medicine, noted that HHS...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login